Sugi Predict
/ Targets
/ BET1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to BET1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
PHASE3 | COMPLETED |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients |
PHASE3 | UNKNOWN |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma |
PHASE1/PHASE2 | RECRUITING |
| Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma |
PHASE1/PHASE2 | WITHDRAWN |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) |
PHASE2 | COMPLETED |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial |
PHASE2 | RECRUITING |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors |
PHASE1 | WITHDRAWN |
| A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer |
PHASE1 | RECRUITING |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors |
PHASE1 | UNKNOWN |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies |
PHASE1 | RECRUITING |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
PHASE1 | RECRUITING |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors |
PHASE1 | SUSPENDED |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer |
PHASE1 | RECRUITING |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers |
PHASE1 | RECRUITING |
| Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV) |
EARLY_PHASE1 | COMPLETED |
| Tolerance in Beekeepers |
nan | RECRUITING |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma |
nan | NO_LONGER_AVAILABLE |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Studying Gene Expression in Samples From Patients With Rhabdoid Tumors |
nan | COMPLETED |
| A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL |
nan | RECRUITING |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia |
nan | COMPLETED |
| Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1 |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a BET1 binder may also engage these)